All Title Author
Keywords Abstract

PLOS ONE  2012 

Dose-Dependent Activation of Putative Oncogene SBSN by BORIS

DOI: 10.1371/journal.pone.0040389

Full-Text   Cite this paper   Add to My Lib

Abstract:

Testis-specific transcription factor BORIS (Brother of the Regulator of Imprinted Sites), a paralog and proposed functional antagonist of the widely expressed CTCF, is abnormally expressed in multiple tumor types and has been implicated in the epigenetic activation of cancer-testis antigens (CTAs). We have reported previously that suprabasin (SBSN), whose expression is restricted to the epidermis, is epigenetically derepressed in lung cancer. In this work, we establish that SBSN is a novel non-CTA target of BORIS epigenetic regulation. With the use of a doxycycline-inducible BORIS expressing vector, we demonstrate that relative BORIS dosage is critical for SBSN activation. At lower concentrations, BORIS induces demethylation of the SBSN CpG island and disruption and activation of chromatin around the SBSN transcription start site (TSS), resulting in a 35-fold increase in SBSN expression in the H358 human lung cancer cell line. Interestingly, increasing BORIS concentrations leads to a subsequent reduction in SBSN expression via chromatin repression. In a similar manner, increase in BORIS concentrations leads to eventual decrease of cell growth and colony formation. This is the first report demonstrating that different amount of BORIS defines its varied effects on the expression of a target gene via chromatin structure reorganization.

References

[1]  Loukinov DI, Pugacheva E, Vatolin S, Pack SD, Moon H, et al. (2002) BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci U S A 99: 6806–6811.
[2]  Klenova EM, Morse HC 3rd, Ohlsson R, Lobanenkov VV (2002) The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol 12: 399–414.
[3]  Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, et al. (2005) Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 65: 7763–7774.
[4]  Renaud S, Loukinov D, Alberti L, Vostrov A, Kwon YW, et al. (2011) BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells. Nucleic Acids Res 39: 862–873.
[5]  Risinger JI, Chandramouli GV, Maxwell GL, Custer M, Pack S, et al. (2007) Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression. Clin Cancer Res 13: 1713–1719.
[6]  Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, et al. (2005) Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 65: 7751–7762.
[7]  Bhan S, Negi SS, Shao C, Glazer CA, Chuang A, et al. (2011) BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer. Clin Cancer Res 17: 4267–4276.
[8]  Sun L, Huang L, Nguyen P, Bisht KS, Bar-Sela G, et al. (2008) DNA methyltransferase 1 and 3B activate BAG-1 expression via recruitment of CTCFL/BORIS and modulation of promoter histone methylation. Cancer Res 68: 2726–2735.
[9]  Glazer CA, Smith IM, Ochs MF, Begum S, Westra W, et al. (2009) Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC. PLoS One 4: e8189.
[10]  Smith IM, Glazer CA, Mithani SK, Ochs MF, Sun W, et al. (2009) Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One 4: e4961.
[11]  Suzuki T, Kosaka-Suzuki N, Pack S, Shin DM, Yoon J, et al. (2010) Expression of a testis-specific form of Gal3st1 (CST), a gene essential for spermatogenesis, is regulated by the CTCF paralogous gene BORIS. Mol Cell Biol 30: 2473–2484.
[12]  Cuffel C, Rivals JP, Zaugg Y, Salvi S, Seelentag W, et al. (2011) Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer 128: 2625–2634.
[13]  Kosaka-Suzuki N, Suzuki T, Pugacheva EM, Vostrov AA, Morse HC 3rd, et al (2011) Transcription factor BORIS (Brother of the Regulator of Imprinted Sites) directly induces expression of a cancer-testis antigen, TSP50, through regulated binding of BORIS to the promoter. J Biol Chem 286: 27378–27388.
[14]  Hoffmann MJ, Muller M, Engers R, Schulz WA (2006) Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. Biochem Pharmacol 72: 1577–1588.
[15]  Nguyen P, Bar-Sela G, Sun L, Bisht KS, Cui H, et al. (2008) BAT3 and SET1A form a complex with CTCFL/BORIS to modulate H3K4 histone dimethylation and gene expression. Mol Cell Biol 28: 6720–6729.
[16]  Fiorentino FP, Giordano A (2011) The tumor suppressor role of CTCF. J Cell Physiol 227: 479–492.
[17]  Deniaud E, Baguet J, Chalard R, Blanquier B, Brinza L, et al. (2009) Overexpression of transcription factor Sp1 leads to gene expression perturbations and cell cycle inhibition. PLoS One 4: e7035.
[18]  Kang Y, Hong JA, Chen GA, Nguyen DM, Schrump DS (2007) Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells. Oncogene 26: 4394–4403.
[19]  Ohlsson R, Lobanenkov V, Klenova E (2010) Does CTCF mediate between nuclear organization and gene expression? Bioessays 32: 37–50.
[20]  Jelinic P, Stehle JC, Shaw P (2006) The testis-specific factor CTCFL cooperates with the protein methyltransferase PRMT7 in H19 imprinting control region methylation. PLoS Biol 4: e355.
[21]  Kholmanskikh O, Loriot A, Brasseur F, De Plaen E, De Smet C (2008) Expression of BORIS in melanoma: lack of association with MAGE-A1 activation. Int J Cancer 122: 777–784.
[22]  Woloszynska-Read A, James SR, Song C, Jin B, Odunsi K, et al. (2010) BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines. Cancer Immun 10: 6.
[23]  Hines WC, Bazarov AV, Mukhopadhyay R, Yaswen P (2010) BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas. PLoS One 5: e9738.
[24]  Renaud S, Pugacheva EM, Delgado MD, Braunschweig R, Abdullaev Z, et al. (2007) Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Res 35: 7372–7388.
[25]  Buffart TE, van Grieken NC, Tijssen M, Coffa J, Ylstra B, et al. (2009) High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch 455: 213–223.
[26]  Park SY, Kim YH, In KH, Chun YH, Park SH (2004) Chromosomal aberrations in Korean nonsmall cell lung carcinomas: degenerate oligonucleotide primed polymerase chain reaction comparative genomic hybridization studies. Cancer Genet Cytogenet 152: 153–157.
[27]  Mkrtichyan M, Ghochikyan A, Loukinov D, Davtyan H, Ichim TE, et al. (2008) DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice. Gene Ther 15: 61–64.
[28]  Mkrtichyan M, Ghochikyan A, Davtyan H, Movsesyan N, Loukinov D, et al. (2011) Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. Cell Immunol 270: 188–197.
[29]  Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong-On P, et al. (2001) Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother 24: 151–161.
[30]  Bazzi H, Fantauzzo KA, Richardson GD, Jahoda CA, Christiano AM (2007) Transcriptional profiling of developing mouse epidermis reveals novel patterns of coordinated gene expression. Dev Dyn 236: 961–970.
[31]  Matsui T, Hayashi-Kisumi F, Kinoshita Y, Katahira S, Morita K, et al. (2004) Identification of novel keratinocyte-secreted peptides dermokine-alpha/-beta and a new stratified epithelium-secreted protein gene complex on human chromosome 19q13.1. Genomics 84: 384–397.
[32]  Park GT, Lim SE, Jang SI, Morasso MI (2002) Suprabasin, a novel epidermal differentiation marker and potential cornified envelope precursor. J Biol Chem 277: 45195–45202.
[33]  Formolo CA, Williams R, Gordish-Dressman H, MacDonald TJ, Lee NH, et al. (2011) Secretome signature of invasive glioblastoma multiforme. J Proteome Res 10: 3149–3159.
[34]  Kim MS, Yamashita K, Baek JH, Park HL, Carvalho AL, et al. (2006) N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res 66: 3409–3418.
[35]  Gaykalova DA, Kulaeva OI, Bondarenko VA, Studitsky VM (2009) Preparation and analysis of uniquely positioned mononucleosomes. Methods Mol Biol 523: 109–123.
[36]  Jenuwein T, Allis CD (2001) Translating the histone code. Science 293: 1074–1080.
[37]  Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, et al. (2008) Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 40: 897–903.
[38]  Bannister AJ, Zegerman P, Partridge JF, Miska EA, Thomas JO, et al. (2001) Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410: 120–124.
[39]  Lachner M, O'Carroll D, Rea S, Mechtler K, Jenuwein T (2001) Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 410: 116–120.
[40]  Hore TA, Deakin JE, Marshall Graves JA (2008) The evolution of epigenetic regulators CTCF and BORIS/CTCFL in amniotes. PLoS Genet 4: e1000169.
[41]  Wong MP, Fung LF, Wang E, Chow WS, Chiu SW, et al. (2003) Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers. Cancer 97: 1263–1270.
[42]  Loukinov D, Ghochikyan A, Mkrtichyan M, Ichim TE, Lobanenkov VV, et al. (2006) Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem 98: 1037–1043.
[43]  Fiorentino FP, Macaluso M, Miranda F, Montanari M, Russo A, et al. (2011) CTCF and BORIS regulate Rb2/p130 gene transcription: a novel mechanism and a new paradigm for understanding the biology of lung cancer. Mol Cancer Res 9: 225–233.
[44]  Pant V, Kurukuti S, Pugacheva E, Shamsuddin S, Mariano P, et al. (2004) Mutation of a single CTCF target site within the H19 imprinting control region leads to loss of Igf2 imprinting and complex patterns of de novo methylation upon maternal inheritance. Mol Cell Biol 24: 3497–3504.
[45]  Xu J, Huo D, Chen Y, Nwachukwu C, Collins C, et al. (2010) CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors. Breast Cancer Res Treat 120: 593–601.
[46]  Chernukhin I, Shamsuddin S, Kang SY, Bergstrom R, Kwon YW, et al. (2007) CTCF interacts with and recruits the largest subunit of RNA polymerase II to CTCF target sites genome-wide. Mol Cell Biol 27: 1631–1648.
[47]  Nguyen P, Cui H, Bisht KS, Sun L, Patel K, et al. (2008) CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region. Cancer Res 68: 5546–5551.
[48]  Pugacheva EM, Suzuki T, Pack SD, Kosaka-Suzuki N, Yoon J, et al. (2010) The structural complexity of the human BORIS gene in gametogenesis and cancer. PLoS One 5: e13872.

Full-Text

comments powered by Disqus